

N-of-1 trials of stimulants versus placebo and each other for Attention Deficit Hyperactivity Disorder in children

Submission date 04/08/2007	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 16/08/2007	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 21/05/2019	Condition category Mental and Behavioural Disorders	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Geoff Mitchell

Contact details
Division of General Practice
The University of Queensland
Brisbane
Australia
4006

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

ADHDAHMACGEN version 2; Also registered in Australian Clinical Trials Registry:
ACTRN12605000507684

Study information

Scientific Title

N-of-1 trials of stimulants versus placebo and each other for Attention Deficit Hyperactivity Disorder in children

Acronym

ADHDIMET

Study objectives

1. N-of-1 trials will improve therapeutic decision making about Attention Deficit Hyperactivity Disorder (ADHD) medications, by educating the doctor and the patient in the use of N-of-1 trial methodology for objective individual patient decision making
2. N-of-1 trials will be able to evaluate individual patient responses to stimulants in terms of relief of ADHD symptoms, and immediate side-effect profile

Ethics approval required

Old ethics approval format

Ethics approval(s)

The University of Queensland Medical Research Ethics Committee and the Mater Misericordiae Hospital Medical Research Ethics Committee approved the study.

Study design

This N-of-1 trial is a randomised, double-blind, cross-over comparison of stimulants (methylphenidate or dexamphetamine) and placebo within an individual patient.

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Attention Deficit Hyperactivity Disorder

Interventions

1. Stimulant versus placebo
2. Stimulant versus stimulant

The stimulants being tested will be dexamphetamine and methylphenidate, compared to placebo and each other. The dose will be individualised by the child's doctor to the optimum

dose without side effects, and will be taken orally at morning and lunchtime. There are two types of trials: treatments will take place in three day or one week periods; each pair of periods will be repeated three times (total of 3 and 6 weeks respectively). Follow-up will be for one year.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Methylphenidate, dexamphetamine

Primary outcome measure

1. Conners' Teacher and Parent self reported revised short form
2. Conners-Wells Adolescent Rating Scales

Outcomes will be measured at baseline and at the end of each treatment period.

Secondary outcome measures

No secondary outcome measures

Overall study start date

01/12/1999

Completion date

01/05/2005

Eligibility**Key inclusion criteria**

1. Any school age patient with a clinical diagnosis of ADHD of at least a month's duration, in the opinion of the attending medical practitioner, who is stabilised on treatment with Ritalin
2. Patient, parent and doctor would like to use the n-of-1 trial methodology to see if the patient is a responder to methylphenidate or dexamphetamine

Participant type(s)

Patient

Age group

Child

Sex

Not Specified

Target number of participants

100

Total final enrolment

86

Key exclusion criteria

1. Advanced arteriosclerosis
2. Symptomatic cardiovascular disease
3. Moderate to severe hypertension
4. Hyperthyroidism
5. Pheochromocytoma
6. Glaucoma
7. Agitated states
8. Anxiety
9. Motor tics
10. Tourette syndrome
11. Monoamine Oxidase Inhibitors (MAOIs) (+/- 14 days)
12. Idiosyncratic reaction to sympathomimetic amines
13. History of drug abuse

Date of first enrolment

01/12/1999

Date of final enrolment

01/05/2005

Locations**Countries of recruitment**

Australia

Study participating centre**Division of General Practice**

Brisbane

Australia

4006

Sponsor information**Organisation**

The University of Queensland (Australia)

Sponsor details

St. Lucia 4029

Brisbane

Australia

4029

-

iharris@uq.edu.au

Sponsor type

University/education

Website

<http://www.uq.edu.au/>

ROR

<https://ror.org/00r9y9422>

Funder(s)

Funder type

Government

Funder Name

General Practice Evaluation Program (GPEP) (Australia)

Funder Name

The Department of Health and Aged Care (Australia)

Funder Name

Queensland Medical Laboratory (Australia)

Funder Name

Mater Misericordiae Health Services (Brisbane, Australia)

Funder Name

The Royal Australian College of General Practitioners (Australia)

Funder Name

National Health and Medical Research Council (Australia) - medical postgraduate research scholarship (ref: 210364)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/06/2006	21/05/2019	Yes	No